Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer

E-ISSN： 2210-3104|4|3|150-162

ISSN： 2210-3090

Source： Recent Patents on Biomarkers, Vol.4, Iss.3, 2014-09, pp. : 150-162

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

The prevalence of cancer in our days remains at high level all over the world. Implementing and improving tools for better diagnostics and prognostics is a very active field of research aimed towards giving the patients the best possible management of their disease. Since the discovery of the presence of cell-free circulating DNA (ccfDNA) in the blood of cancer patients, it has been proposed as a tool for tumor diagnosis, follow-up of treatment and prognosis assessment. In fact, the strong link with molecular alterations found in the tumor has demonstrated effective as a prognostic tool specially regarding invasive types of cancers. Today, the circulating plasma tumor DNA (cptDNA), also known as liquid biopsy, promises an outstanding clinical test in routine cancer patient management, which is currently used in numerous clinical trials as a secondary parameter to follow outcome of the treatments being investigated. Besides describing patents covering specific markers, several patents have been recently filed for methods of cptDNA analysis. In this review, we aim to provide with a succinct summary of the current application of cptDNA as a tool for clinical management of the cancer patient.